Dynavax Technologies Revenue 2010-2023 | DVAX
Dynavax Technologies revenue from 2010 to 2023. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Dynavax Technologies Annual Revenue
(Millions of US $) |
| 2022 |
$723 |
| 2021 |
$439 |
| 2020 |
$47 |
| 2019 |
$35 |
| 2018 |
$8 |
| 2017 |
$0 |
| 2016 |
$11 |
| 2015 |
$4 |
| 2014 |
$11 |
| 2013 |
$11 |
| 2012 |
$10 |
| 2011 |
$22 |
| 2010 |
$24 |
| 2009 |
$40 |
Dynavax Technologies Quarterly Revenue
(Millions of US $) |
| 2023-03-31 |
$47 |
| 2022-12-31 |
$184 |
| 2022-09-30 |
$168 |
| 2022-06-30 |
$256 |
| 2022-03-31 |
$114 |
| 2021-12-31 |
$195 |
| 2021-09-30 |
$108 |
| 2021-06-30 |
$53 |
| 2021-03-31 |
$83 |
| 2020-12-31 |
$20 |
| 2020-09-30 |
$13 |
| 2020-06-30 |
$3 |
| 2020-03-31 |
$11 |
| 2019-12-31 |
$11 |
| 2019-09-30 |
$11 |
| 2019-06-30 |
$8 |
| 2019-03-31 |
$6 |
| 2018-12-31 |
$5 |
| 2018-09-30 |
$1 |
| 2018-06-30 |
$1 |
| 2018-03-31 |
$0 |
| 2017-12-31 |
$0 |
| 2017-09-30 |
$0 |
| 2017-06-30 |
$0 |
| 2017-03-31 |
$0 |
| 2016-12-31 |
$7 |
| 2016-09-30 |
$0 |
| 2016-06-30 |
$3 |
| 2016-03-31 |
$1 |
| 2015-12-31 |
$1 |
| 2015-09-30 |
$1 |
| 2015-06-30 |
$2 |
| 2015-03-31 |
$1 |
| 2014-12-31 |
$2 |
| 2014-09-30 |
$2 |
| 2014-06-30 |
$3 |
| 2014-03-31 |
$3 |
| 2013-12-31 |
$3 |
| 2013-09-30 |
$3 |
| 2013-06-30 |
$3 |
| 2013-03-31 |
$2 |
| 2012-12-31 |
$2 |
| 2012-09-30 |
$3 |
| 2012-06-30 |
$3 |
| 2012-03-31 |
$2 |
| 2011-12-31 |
$11 |
| 2011-09-30 |
$1 |
| 2011-06-30 |
$7 |
| 2011-03-31 |
$2 |
| 2010-12-31 |
$2 |
| 2010-09-30 |
$12 |
| 2010-06-30 |
$2 |
| 2010-03-31 |
$8 |
| 2009-12-31 |
$2 |
| 2009-09-30 |
$3 |
| 2009-06-30 |
$16 |
| 2009-03-31 |
$19 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$1.430B |
$0.723B |
|
Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax's clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation.
|
